Literature DB >> 25958346

Correlation of functional GRIN2A gene promoter polymorphisms with schizophrenia and serum D-serine levels.

Rui Liu1, Wei Dang2, Ying Du3, Qiong Zhou3, Zhaohui Liu4, Kai Jiao5.   

Abstract

Schizophrenia is a severe, complex mental disorder. Abnormal glutamate neurotransmission mediated by decreased expression of N-methyl-d-aspartic acid receptors (NMDArs) and its endogenous co-agonist d-serine (d-Ser) has been proposed as one of the hypotheses of the pathogenesis of schizophrenia. GRIN2A gene promoter polymorphism causes changes in the regulation of the expression of NMDAr subunit genes. Our study is aimed at evaluating a possible association between GRIN2A promoter GT polymorphisms and schizophrenia in the Han Chinese population in Shaanxi and the relationship between serum d-Ser levels and GRIN2A (GT)n in schizophrenia. Four hundred and twenty patients with schizophrenia and 410 healthy individuals were recruited in this study and GRIN2A (GT)n repeats as well as serum d-Ser levels were measured in all of the subjects. Nineteen alleles were found in (GT)n locus. The allele frequency of (GT)21, (GT)22 and (GT)23 in schizophrenic subjects was significantly lower compared with the mentally healthy controls, while the allele (GT)26 was significantly more frequent than in normal persons. Transcriptional activity of GRIN2A promoter was gradually suppressed with the increase in the length of the (GT)n repeats. d-Ser levels in the serum of the GRIN2A (GT)21 schizophrenic patients were significantly lower than those of the GRIN2A (GT)21 healthy control. A significant correlation between serum d-Ser levels and GRIN2A (GT)21 in schizophrenia was detected. GRIN2A (GT)21 may play a significant role in the etiology of schizophrenia among the Chinese Han population of Shaanxi.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  GRIN2A; GT; Schizophrenia; Single nucleotide polymorphism; d-Serine

Mesh:

Substances:

Year:  2015        PMID: 25958346     DOI: 10.1016/j.gene.2015.05.011

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  6 in total

1.  Bridging the Gap between Genes and Language Deficits in Schizophrenia: An Oscillopathic Approach.

Authors:  Elliot Murphy; Antonio Benítez-Burraco
Journal:  Front Hum Neurosci       Date:  2016-08-23       Impact factor: 3.169

2.  Interaction between prenatal pesticide exposure and a common polymorphism in the PON1 gene on DNA methylation in genes associated with cardio-metabolic disease risk-an exploratory study.

Authors:  Ken Declerck; Sylvie Remy; Christine Wohlfahrt-Veje; Katharina M Main; Guy Van Camp; Greet Schoeters; Wim Vanden Berghe; Helle R Andersen
Journal:  Clin Epigenetics       Date:  2017-04-05       Impact factor: 6.551

3.  Regulatory Architecture of the Neuronal Cacng2/Tarpγ2 Gene Promoter: Multiple Repressive Domains, a Polymorphic Regulatory Short Tandem Repeat, and Bidirectional Organization with Co-regulated lncRNAs.

Authors:  B P A Corney; C L Widnall; D J Rees; J S Davies; V Crunelli; D A Carter
Journal:  J Mol Neurosci       Date:  2018-11-26       Impact factor: 3.444

4.  Glutamate ionotropic receptor NMDA type subunit 2A (GRIN2A) gene polymorphism (rs4998386) and Parkinson's disease susceptibility: A meta-analysis.

Authors:  Gaurav Nepal; Jessica Holly Rehrig; Rajeev Ojha
Journal:  Aging Med (Milton)       Date:  2019-07-23

Review 5.  Glycine Signaling in the Framework of Dopamine-Glutamate Interaction and Postsynaptic Density. Implications for Treatment-Resistant Schizophrenia.

Authors:  Andrea de Bartolomeis; Mirko Manchia; Federica Marmo; Licia Vellucci; Felice Iasevoli; Annarita Barone
Journal:  Front Psychiatry       Date:  2020-05-14       Impact factor: 4.157

6.  Clinical and biochemical study of d-serine metabolism among schizophrenia patients.

Authors:  Hamdy N El-Tallawy; Tahia H Saleem; Abdallah Maa El-Ebidi; Mohammed H Hassan; Romany H Gabra; Wafaa Ma Farghaly; Nagwa Abo El-Maali; Hoda S Sherkawy
Journal:  Neuropsychiatr Dis Treat       Date:  2017-04-10       Impact factor: 2.570

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.